Study finds scleral allograft reinforced cyclodialysis effective for POAG management

Scleral allograft reinforced cyclodialysis, performed alongside cataract surgery, is an effective and well-tolerated procedure for reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG), with no serious complications reported, according to a study.

The single-center case series followed 31 eyes over 24 months after undergoing uveoscleral outflow enhancement with phacoemulsification.

At 12 months post-surgery, 74% of eyes achieved a ≥20% reduction in IOP with the same or fewer medications. Mean IOP dropped by 34% from a baseline of 21.9 mmHg to 12.62 mmHg, with a reduction in glaucoma medications from 1.22 to 0.55 on average. The procedure was well tolerated, with no serious ocular complications reported.

Study author Robert N. Weinreb, MD, Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego, stated in a company press release: “This study marks a significant advancement in glaucoma surgery by safely and effectively targeting the uveoscleral pathway through a minimally invasive, bio-interventional approach. It represents a groundbreaking, hardware-free solution utilizing next-generation homologous bio-tissue materials for superior biocompatibility.”

Reference
Calvo E, De Francesco T, Vera L, et al. Bio-interventional uveoscleral outflow enhancement surgery for primary open-angle glaucoma: 2-year results of cyclodialysis with scleral allograft reinforcement. Ophthalmol Sci. 2025;5(2):100727. doi:10.1016/j.xops.2025.100727.